BioMarin price target raised to $47 from $41 at Brean Murray Brean Murray raised its price target on BioMarin following positive preliminary Phase 2 results with PEG-PAL in phenylketonuria (PKU). The firm said the results were a positive surprise and with the addition of it in their model it causes them to raise their price target. Shares are Buy rated.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Subscribe for More Information